GOODMAN AND GILMAN'S THE
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
1⃣
Reference
Ch. 1 — Drug Discovery: Natural Products → Lead Identification
Stem
A 62-year-old patient with refractory neuropathic pain asks why
some modern drugs were first discovered from plants. A
medicinal chemist explains that many approved analgesics
originated from natural products because of complex scaffolds
that interact with biological targets. Which principle best
explains why a complex natural product scaffold often provides
,a superior starting point for lead optimization compared with a
simple synthetic fragment?
Options
A. Natural product scaffolds are inherently more polar, which
increases oral bioavailability.
B. Complex scaffolds present multiple defined stereocenters
and topological features that match biological macromolecule
surfaces.
C. Simple synthetic fragments always have lower metabolic
clearance than natural products.
D. Natural products are less likely to interact with multiple
targets, reducing off-target effects.
Correct answer
B
Rationale — Correct
B is correct because complex natural scaffolds often contain
stereochemistry and three-dimensional topologies that
complement protein binding sites, giving higher initial affinity
and selectivity for biological targets and better vectors for SAR
during optimization. This structural complexity aids efficient
lead development.
Rationale — Incorrect
A: Polarity alone does not guarantee oral bioavailability; many
natural products are lipophilic and require modification.
C: Simple fragments often have higher clearance due to lack of
steric shielding; metabolic fate is not uniformly lower.
,D: Natural products frequently interact with multiple targets
(polypharmacology), which can be advantageous or
problematic.
Teaching point
Three-dimensional complexity and stereochemistry of natural
products facilitate target complementarity.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
2️⃣
Reference
Ch. 1 — Target Identification & Validation
Stem
A biotech company has a monoclonal antibody candidate
against a newly discovered membrane enzyme implicated in
heart failure. Preclinical knockdown of the target improved
cardiac output in rodents, but some human genetic variants of
the enzyme correlate with increased ACE inhibitor sensitivity.
When deciding whether the enzyme is a viable clinical target,
which translational consideration is most critical?
Options
A. The target’s in vitro expression level in HEK293 cells.
B. Conservation of target function and pathway across species
and human genetic evidence of causality.
, C. Ease of producing a high-yield recombinant protein for
screening.
D. The antibody’s ability to bind the rodent ortholog with higher
affinity than the human protein.
Correct answer
B
Rationale — Correct
B is correct because translational viability hinges on conserved
biological role and human genetic/epidemiologic evidence
linking the target to disease—this predicts whether modulating
the target will have a therapeutic effect in humans. Cross-
species functional conservation informs relevance of animal
models.
Rationale — Incorrect
A: HEK293 expression is useful for assays but does not ensure
disease relevance or translational potential.
C: Production feasibility matters operationally but not for
biological validation.
D: Preferably the antibody binds human target; higher rodent
affinity increases risk of misrepresenting human pharmacology.
Teaching point
Target validation requires conserved function and human
genetic evidence of disease causality.
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
1⃣
Reference
Ch. 1 — Drug Discovery: Natural Products → Lead Identification
Stem
A 62-year-old patient with refractory neuropathic pain asks why
some modern drugs were first discovered from plants. A
medicinal chemist explains that many approved analgesics
originated from natural products because of complex scaffolds
that interact with biological targets. Which principle best
explains why a complex natural product scaffold often provides
,a superior starting point for lead optimization compared with a
simple synthetic fragment?
Options
A. Natural product scaffolds are inherently more polar, which
increases oral bioavailability.
B. Complex scaffolds present multiple defined stereocenters
and topological features that match biological macromolecule
surfaces.
C. Simple synthetic fragments always have lower metabolic
clearance than natural products.
D. Natural products are less likely to interact with multiple
targets, reducing off-target effects.
Correct answer
B
Rationale — Correct
B is correct because complex natural scaffolds often contain
stereochemistry and three-dimensional topologies that
complement protein binding sites, giving higher initial affinity
and selectivity for biological targets and better vectors for SAR
during optimization. This structural complexity aids efficient
lead development.
Rationale — Incorrect
A: Polarity alone does not guarantee oral bioavailability; many
natural products are lipophilic and require modification.
C: Simple fragments often have higher clearance due to lack of
steric shielding; metabolic fate is not uniformly lower.
,D: Natural products frequently interact with multiple targets
(polypharmacology), which can be advantageous or
problematic.
Teaching point
Three-dimensional complexity and stereochemistry of natural
products facilitate target complementarity.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
2️⃣
Reference
Ch. 1 — Target Identification & Validation
Stem
A biotech company has a monoclonal antibody candidate
against a newly discovered membrane enzyme implicated in
heart failure. Preclinical knockdown of the target improved
cardiac output in rodents, but some human genetic variants of
the enzyme correlate with increased ACE inhibitor sensitivity.
When deciding whether the enzyme is a viable clinical target,
which translational consideration is most critical?
Options
A. The target’s in vitro expression level in HEK293 cells.
B. Conservation of target function and pathway across species
and human genetic evidence of causality.
, C. Ease of producing a high-yield recombinant protein for
screening.
D. The antibody’s ability to bind the rodent ortholog with higher
affinity than the human protein.
Correct answer
B
Rationale — Correct
B is correct because translational viability hinges on conserved
biological role and human genetic/epidemiologic evidence
linking the target to disease—this predicts whether modulating
the target will have a therapeutic effect in humans. Cross-
species functional conservation informs relevance of animal
models.
Rationale — Incorrect
A: HEK293 expression is useful for assays but does not ensure
disease relevance or translational potential.
C: Production feasibility matters operationally but not for
biological validation.
D: Preferably the antibody binds human target; higher rodent
affinity increases risk of misrepresenting human pharmacology.
Teaching point
Target validation requires conserved function and human
genetic evidence of disease causality.
